Paid Clinical Trials Fayetteville

Discover 181 paid clinical trials in Fayetteville, Arkansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 181

Saruparib

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Springdale AR, Little Rock AR, Westwood KS, Wichita KSshow 114 more

Code:

NCT06120491

Conditions

Metastatic Castration-Sensitive Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Saruparib

Placebo

Abiraterone Acetate

Darolutamide

Enzalutamide

Ruxolitinib Cream

Recruiting

PHASE3

Sponsor:

Incyte Corporation

Location:

Fayetteville AR, Hot Springs AR, Longview TX, Saint Joseph MOshow 59 more

Code:

NCT06548360

Conditions

NonSegmental Vitiligo

Eligibility Criteria

Sex: All

Age: 2 - 11

Healthy Volunteers: Not accepted

Interventions

Ruxolitinib Cream

Vehicle Cream

Observational Study

Recruiting

Sponsor:

National Cancer Institute (NCI)

Location:

Fort Smith AR, Branson MO, Joplin MO, Springfield MOshow 94 more

Code:

NCT02474160

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Metastatic Malignant Solid Neoplasm

Recurrent Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cytology Specimen Collection Procedure

SPN-812

Recruiting

Sponsor:

Supernus Pharmaceuticals, Inc.

Location:

Fayetteville AR, Little Rock AR, Memphis TN, Dallas TXshow 36 more

Code:

NCT04781140

Conditions

Attention-Deficit/Hyperactivity Disorder

Eligibility Criteria

Sex: All

Age: 48 - 69

Healthy Volunteers: Not accepted

Interventions

100mg SPN-812

Placebo

MILD

Recruiting

Sponsor:

Vertos Medical, Inc.

Location:

Fayetteville AR, Rogers AR, Siloam Springs AR, Pittsburg KSshow 1071 more

Code:

NCT03072927

Conditions

Lumbar Spinal Stenosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MILD

Interspinous Process Decompression

Bupropion

Recruiting

PHASE3

Sponsor:

University of Rochester NCORP Research Base

Location:

Fort Smith AR, Branson MO, Joplin MO, Springfield MOshow 290 more

Code:

NCT03996265

Conditions

Be Diagnosed With Cancer and Have Completed Systemic Therapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bupropion Hydrochloride Controlled-release

Placebo Administration

Quality-of-Life Assessment

Questionnaire Administration

Steroids & TKIs

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Fort Smith AR, Joplin MO, Springfield MO, Bolivar MOshow 142 more

Code:

NCT04530565

Conditions

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Blinatumomab

Bone Marrow Aspiration and Biopsy

Cyclophosphamide

Cytarabine

Povorcitinib

Recruiting

PHASE3

Sponsor:

Incyte Corporation

Location:

Fayetteville AR, Oklahoma City OK, Saint Joseph MO, Dallas TXshow 47 more

Code:

NCT06516965

Conditions

Prurigo Nodularis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Povorcitinib

Placebo

TAK-279

Recruiting

PHASE3

Sponsor:

Takeda

Location:

Fort Smith AR, Hot Springs AR, Frisco TX, Dallas TXshow 85 more

Code:

NCT06550076

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAK-279

Chemotherapy

Recruiting

PHASE2

Sponsor:

SWOG Cancer Research Network

Location:

Fort Smith AR, Branson MO, Joplin MO, Springfield MOshow 214 more

Code:

NCT05040360

Conditions

Metastatic Malignant Neoplasm in the Liver

Pancreatic Neuroendocrine Tumor

Stage I Pancreatic Neuroendocrine Tumor AJCC v8

Stage II Pancreatic Neuroendocrine Tumor AJCC v8

Stage III Pancreatic Neuroendocrine Tumor AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Capecitabine

Temozolomide